Comparative Pharmacology
Head-to-head clinical analysis: DIUCARDIN versus METAHYDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIUCARDIN versus METAHYDRIN.
DIUCARDIN vs METAHYDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.
Metahydrin (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing excretion of water, sodium, chloride, and potassium.
Hydrochlorothiazide 25-50 mg orally once daily, titrated based on response. Maximum dose 100 mg/day.
Oral, 50-100 mg once daily. Maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 18-24 hours in normal renal function. This prolongs significantly in renal impairment, requiring dose adjustment.
18-30 hours (clinically relevant for once-daily dosing in hypertension; prolonged in renal impairment)
Primarily renal excretion: approximately 60-70% of the dose is excreted unchanged in urine within 24 hours. Biliary/fecal elimination accounts for about 20-30%, with some enterohepatic circulation.
Renal: 30% (fecal: 70% as unabsorbed drug, primarily biliary elimination; <1% unchanged in urine)
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic